WO2006014683A3 - Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2 - Google Patents

Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2 Download PDF

Info

Publication number
WO2006014683A3
WO2006014683A3 PCT/US2005/025656 US2005025656W WO2006014683A3 WO 2006014683 A3 WO2006014683 A3 WO 2006014683A3 US 2005025656 W US2005025656 W US 2005025656W WO 2006014683 A3 WO2006014683 A3 WO 2006014683A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycoform
immunoglobulins
predominantly
relates
present
Prior art date
Application number
PCT/US2005/025656
Other languages
English (en)
Other versions
WO2006014683A2 (fr
Inventor
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Original Assignee
Glycofi Inc
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycofi Inc, Tillman U Gerngross, Huijuan Li, Stefan Wildt filed Critical Glycofi Inc
Priority to EP05790299A priority Critical patent/EP1771477A2/fr
Priority to CA002573842A priority patent/CA2573842A1/fr
Priority to AU2005269763A priority patent/AU2005269763A1/en
Priority to JP2007522676A priority patent/JP2008515772A/ja
Publication of WO2006014683A2 publication Critical patent/WO2006014683A2/fr
Publication of WO2006014683A3 publication Critical patent/WO2006014683A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention concerne des compositions de glycoprotéines d'immunoglobulines présentant des structures N- glycane prédominantes sur une glycoprotéine d'immunoglobuline conférant une fonction effectrice spécifique. L'invention concerne également des compositions pharmaceutiques contenant un anticorps présentant une structure N- glycane caractéristique enrichie, ladite structure N glycane étant une glycoforme Gal2GlcNAc2Man3GlcNAc2.exempte de fucose.
PCT/US2005/025656 2004-07-21 2005-07-19 Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2 WO2006014683A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05790299A EP1771477A2 (fr) 2004-07-21 2005-07-19 Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2
CA002573842A CA2573842A1 (fr) 2004-07-21 2005-07-19 Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2
AU2005269763A AU2005269763A1 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a Gal2GlcNac2Man3GlcNac2 glycoform
JP2007522676A JP2008515772A (ja) 2004-07-21 2005-07-19 Ｇａｌ２ＧｌｃＮＡｃ２Ｍａｎ３ＧｌｃＮＡｃ２グリコフォームを支配的に含む免疫グロブリン

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59005204P 2004-07-21 2004-07-21
US59003004P 2004-07-21 2004-07-21
US60/590,030 2004-07-21
US60/590,052 2004-07-21

Publications (2)

Publication Number Publication Date
WO2006014683A2 WO2006014683A2 (fr) 2006-02-09
WO2006014683A3 true WO2006014683A3 (fr) 2006-06-08

Family

ID=35502713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025656 WO2006014683A2 (fr) 2004-07-21 2005-07-19 Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2

Country Status (5)

Country Link
EP (1) EP1771477A2 (fr)
JP (1) JP2008515772A (fr)
AU (1) AU2005269763A1 (fr)
CA (1) CA2573842A1 (fr)
WO (1) WO2006014683A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102333872B (zh) * 2009-02-25 2014-07-09 默沙东公司 在糖工程化的酵母巴斯德毕赤酵母中对半乳糖同化途径的代谢工程化
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008482A2 (fr) * 2006-07-13 2008-01-17 Genentech, Inc. Polypeptides de liaison à br3 modifiés
PE20080980A1 (es) 2006-10-12 2008-09-02 Genentech Inc Anticuerpos anti-linfotoxina alfa
WO2009146362A1 (fr) 2008-05-30 2009-12-03 Glycofi, Inc. Souche de levure destinée à la production de protéines avec un galactose terminal lié par une liaison alpha-1,3
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
US8458171B2 (en) 2009-01-30 2013-06-04 Google Inc. Identifying query aspects
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
EP2741769B1 (fr) * 2011-08-10 2019-01-02 Laboratoire Français du Fractionnement et des Biotechnologies Anticorps fortement galactosylés
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014125374A2 (fr) 2013-02-13 2014-08-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Anticorps anti-tnf alpha hautement galactosylés et leurs utilisations
TW201446962A (zh) 2013-02-13 2014-12-16 Lab Francais Du Fractionnement 具有修飾的糖化作用之蛋白質及其製造方法
EP2830651A4 (fr) 2013-03-12 2015-09-02 Abbvie Inc Anticorps humains qui se lient au tnf-alpha et leurs procédés de préparation
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
EP3052640A2 (fr) 2013-10-04 2016-08-10 AbbVie Inc. Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056914A1 (fr) * 2001-12-27 2003-07-17 Glycofi, Inc. Procede d'ingenierie de structures de carbohydrates de type mammalien

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056914A1 (fr) * 2001-12-27 2003-07-17 Glycofi, Inc. Procede d'ingenierie de structures de carbohydrates de type mammalien

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOBROWICZ P ET AL: "Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose", GLYCOBIOLOGY, IRL PRESS,, GB, vol. 14, no. 9, 9 June 2004 (2004-06-09), pages 757 - 766, XP002354412, ISSN: 0959-6658 *
HAMILTON S R ET AL: "Production of complex human glycoproteins in yeast", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 301, no. 5637, 29 August 2003 (2003-08-29), pages 1244 - 1246, XP002267832, ISSN: 0036-8075 *
ROUTIER FRANCOISE H ET AL: "The glycosylation pattern of a humanized IgGI antibody (D1.3) expressed in CHO cells", GLYCOCONJUGATE JOURNAL, vol. 14, no. 2, 1997, pages 201 - 207, XP002375244, ISSN: 0282-0080 *
SCHWIENTEK TILO ET AL: "Golgi localization and in vivo activity of a mammalian glycosyltransferase (human beta-1,4-galactosyltransferase) in yeast", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 7, 1996, pages 3398 - 3405, XP002375245, ISSN: 0021-9258 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8883483B2 (en) 2000-06-28 2014-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
CN102333872B (zh) * 2009-02-25 2014-07-09 默沙东公司 在糖工程化的酵母巴斯德毕赤酵母中对半乳糖同化途径的代谢工程化

Also Published As

Publication number Publication date
EP1771477A2 (fr) 2007-04-11
CA2573842A1 (fr) 2006-02-09
WO2006014683A2 (fr) 2006-02-09
AU2005269763A1 (en) 2006-02-09
JP2008515772A (ja) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2006014683A3 (fr) Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2
WO2006071856A3 (fr) Immunoglobulines comprenant principalement une glycoforme man5glcnac2
WO2006066568A3 (fr) Anticorps
WO2008094538A3 (fr) Épitopes de lymphocytes t régulateurs, compositions et utilisations de ceux-ci
WO2007147122A3 (fr) Anticorps monoclonaux qui reconnaissent sélectivement des composés de méthamphétamine et de type méthamphétamine
IL184152A (en) Monoclonal antibodies against nkg2a, preparations containing them, their use in drug preparation, methods of manufacture, and methods used in
WO2007129895A3 (fr) Anticorps monoclonal antagoniste anti-cd40 humain
WO2006023420A3 (fr) Antagonistes de l'integrine possedant une action cytotoxique a mediation cellulaire dependante de l'anticorps amelioree
WO2008091798A3 (fr) Anticorps de ca9 optimises et methodes d'utilisation associees
WO2008022152A3 (fr) Anticorps optimisés ciblant cd19
WO2005074970A3 (fr) Complément alimentaire neuroprotecteur
IL222756A0 (en) Antibodies and antigen-binding fragments thereof that bind to a sclerostin polypeptide, compositions containing the same and methods for the production thereof
WO2006104989A3 (fr) Anticorps a regions fc modifiees et utilisations
WO2006050280A3 (fr) Anticorps et antigenes anti-virus respiratoire syncytial et leurs utilisations
WO2007008583A3 (fr) Resultats et application ameliores d'epreuves de comparaison d'expressions proteiniques
WO2007050569A3 (fr) Films de polypeptide multicouches et procedes
AU2003233992A1 (en) Functional element for attaching to a sheet metal part, composite component produced from said element and method for attaching the functional element to a sheet metal part
EP1647596A4 (fr) Anticorps monoclonal dirige contre la glycoproteine membranaire plaquettaire vi
WO2004046186A3 (fr) Intracorps
WO2006014726A3 (fr) Immunoglobulines comprenant principalement une glycoforme man5glcnac2
EP1344827A3 (fr) Protéines antigel de basidiomycètes
WO2006019955A3 (fr) Methodes et compositions antivirales
WO2004004639A3 (fr) Nouvelle formulation stable
WO2004075021A3 (fr) Procedes de modelisation moleculaire
FR2855557B1 (fr) Volet de tuyere a duree de vie augmentee pour turbomoteurs d'avion.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2573842

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005790299

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007522676

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580024664.0

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005269763

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1206/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005269763

Country of ref document: AU

Date of ref document: 20050719

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005269763

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005790299

Country of ref document: EP